PrimeCog: Primary Care Cognitive Testing

Mental Health Issue Clinical Trial

— PrimeCog  

Official title:

PrimeCog: Cognitive Profile, Psychosocial Characteristics, Brain MRI and Biomarkers for Stress and Neurodegeneration in Patients With Depression or Stress Induced Exhaustion Disorder in Primary Care.

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06346535
• Other study ID #: 2022-05703-01
• Status: Recruiting
• Start date: April 1, 2024
• Est. completion date: April 1, 2029

Study information

• Verified date: April 2024
• Source: Region Östergötland
• Contact: Hanna Israelssion Larsen, PhD
• Phone: +46738317008
• Email: hanna.israelsson.larsen[@]regionostergotland.se
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The PrimeCog study aims to describe the symptomatology and pathophysiology of stress-induced exhaustion disorder (SED) and major depressive disorder (MDD) compared to healthy controls (HC). The participants will be recruited at primary care centers, and samples of blood, saliva, and hair will be collected. Digital questionnaires covering psychosocial variables and screening instruments for the detection of depression, anxiety, etc., along with a digital cognitive test battery, will be performed at home. Subsequently, an MRI of the brain will be performed, and analysis of biomarkers for stress, inflammation, and neurodegeneration will be conducted. These procedures will be repeated after twelve and twenty-four months. The study will investigate differences in the biomarkers, neuroimaging findings, and cognitive abilities between patients with SED, MDD, and controls over time. Associations between the symptom severity of MDD/SED and psychosocial variables, cognition, MRI, and the biomarkers will also be examined. The aim is to provide new diagnostic tools for differentiation between MDD and SED and guide individualized treatment based on underlying pathophysiology and cognitive function. All necessary competences for conducting this extensive study are represented within the research group. The PrimeCog study is unique in its comprehensive design, addressing knowledge gaps, and directly comparing these diagnoses over time in primary care, where patients are typically treated.

Description:

Research problems and specific questions Major depressive disorder (MDD) and stress induced exhaustion disorder (SED) are two growing public health concerns in primary care, causing individual suffering and affecting work productivity. MDD and SED call for different treatment strategies, but diagnosis differentiation pose several difficulties. Both conditions are linked to stress-related factors at work, and prescribed sick leave is a common treatment strategy. The main reasons for sick leave in DEP and UMS is cognitive difficulties, but no objective measures of cognition is used today. The aim of the PrimeCog project is to provide new diagnostic tools for differentiation between MDD and SED and guide individualized treatment based on cognitive function and underlying pathophysiology. Data and method The project is a multicenter longitudinal, prospective research project on patients with newly diagnosed MDD or SED and healthy controls, n=100/group. The participants will be recruited at primary care centers. Data is collected through a digital cognitive test battery carried out at home, a questionnaire with screening scales and psychosocial risk factors, biomarkers in blood, saliva and hair, and a magnetic resonance imaging (MRI) of the brain. These procedures will be repeated after 12 and 24 months. Societal relevance and utilization New diagnostic tools are needed for DEP and UMS in primary care to improve differential diagnosis and to individualize treatment in order to get the right intervention and treatment as quickly as possible. This could hypothetically contribute to shorter illness duration and reduce the length of sick leave. By investigating digital cognitive testing in primary care patients with MDD or SED, the PrimeCog project seeks to enhance diagnosis and follow-up which may prevent negative outcomes for individuals and benefit society by advancing mental health care as a whole. Digital cognitive testing is a new tool in primary care, and potentially both time- and cost-effective approach for objectively measuring cognitive symptoms.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 300
• Est. completion date: April 1, 2029
• Est. primary completion date: April 1, 2027
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

1. adults 18 to 65 years old;

2. fluent in Swedish;

3. corrected to normal vision and hearing;

4. (for cases), newly diagnosed with MDD or SED (i.e., received as new diagnosis at the visit to the physician) according to the diagnostic criteria from DSM-V (MDD) and the Swedish Board of Health and Welfare (SED)

Exclusion Criteria:

1. already ongoing treatment for MDD/SED or previous diagnosis of MDD/SED within the last year;

2. history of serious mental illness (defined as mental illness that has required psychiatric in-patient care);

3. acute cerebrovascular event or severe head trauma in the last 6 months;

4. known cognitive impairment;

5. substance dependence, ongoing or past;

6. motor disability or impairment affecting interaction with the digital tests;

7. photosensitive epilepsy or -migraines. For the MRI subgroup, any contraindication to MRI is an exclusion criterion.

Related Conditions & MeSH terms

• Cognitive Symptom
• Mental Health Issue
• Neurobehavioral Manifestations
• Primary Health Care

Intervention

Diagnostic Test:
• Cognitive Testing
Digital Cognitive Testing performed at home.

Locations

Country	Name	City	State
Sweden	Region Ostergotland, primary care centrum	Linköping	Ostergotland

Sponsors (1)

Lead Sponsor	Collaborator
Region Östergötland

Country where clinical trial is conducted

Sweden, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Cognitive Test Results regarding attention and processing speed	How do cognitive test results regarding attention and processing speed measured by TMT-A vary between individuals with MDD/SED and HC?	At baseline, i.e. at diagnosis, at first study-specific follow-up (12 months from baseline), and at second study-specific follow-up (24 months from baseline)
Primary	Cognitive Test Results regarding attention and processing speed	How do cognitive test results regarding attention and processing speed measured by TMT-B vary between individuals with MDD/SED and HC?	At baseline, i.e. at diagnosis, at first study-specific follow-up (12 months from baseline), and at second study-specific follow-up (24 months from baseline)
Primary	Cognitive Test Results regarding attention and processing speed	How do cognitive test results regarding attention and processing speed measured by SDPTvary between individuals with MDD/SED and HC?	At baseline, i.e. at diagnosis, at first study-specific follow-up (12 months from baseline), and at second study-specific follow-up (24 months from baseline)
Primary	Cognitive Test Results regarding attention and processing speed	How do cognitive test results regarding attention and processing speed measured by Reaction Time Test Simple vary between individuals with MDD/SED and HC?	At baseline, i.e. at diagnosis, at first study-specific follow-up (12 months from baseline), and at second study-specific follow-up (24 months from baseline)
Primary	Cognitive Test Results regarding memory	How do cognitive test results regarding memory, measured by Corsi Span forward and backward, vary between individuals with MDD/SED and HC?	At baseline, i.e. at diagnosis, at first study-specific follow-up (12 months from baseline), and at second study-specific follow-up (24 months from baseline)
Primary	Cognitive Test Results regarding memory	How do cognitive test results regarding memory, measured by RAVLT Learning and Recall vary between individuals with MDD/SED and HC?	At baseline, i.e. at diagnosis, at first study-specific follow-up (12 months from baseline), and at second study-specific follow-up (24 months from baseline)
Primary	Cognitive Test Results regarding executive function	How do cognitive test results regarding executive functions, measured by TMT-B, vary between individuals with MDD/SED and HC?	At baseline, i.e. at diagnosis, at first study-specific follow-up (12 months from baseline), and at second study-specific follow-up (24 months from baseline)
Primary	Cognitive Test Results regarding executive function	How do cognitive test results regarding executive functions, measured by Reaction Time Test Complex (or CPT) vary between individuals with MDD/SED and HC?	At baseline, i.e. at diagnosis, at first study-specific follow-up (12 months from baseline), and at second study-specific follow-up (24 months from baseline)
Primary	Cognitive Test Results regarding executive function	How do cognitive test results regarding executive functions, measured by Stroop Test vary between individuals with MDD/SED and HC?	At baseline, i.e. at diagnosis, at first study-specific follow-up (12 months from baseline), and at second study-specific follow-up (24 months from baseline)
Primary	Cognitive Test Results regarding language	How do cognitive test results regarding language, measured by FAS vary between individuals with MDD/SED and HC?	At baseline, i.e. at diagnosis, at first study-specific follow-up (12 months from baseline), and at second study-specific follow-up (24 months from baseline)
Primary	Cognitive Test Results regarding language	How do cognitive test results regarding language, measured by Boston Naming Test vary between individuals with MDD/SED and HC?	At baseline, i.e. at diagnosis, at first study-specific follow-up (12 months from baseline), and at second study-specific follow-up (24 months from baseline)
Primary	Cognitive Test Results regarding visuospatial capacity	How do cognitive test results regarding visuospatial capacity measured by: Cube Copying Test, vary between individuals with MDD/SED and HC?	At baseline, i.e. at diagnosis, at first study-specific follow-up (12 months from baseline), and at second study-specific follow-up (24 months from baseline)
Secondary	MRI features, measured by morphological and quantitative MR sequences of the brain	How do morphological as well as quantitative MR sequences, with and without intravenous contrast agent with following vary between individuals with MDD/SED and HC?	At baseline, i.e. at diagnosis, at first study-specific follow-up (12 months from baseline), and at second study-specific follow-up (24 months from baseline)
Secondary	Biochemical Profile in blood regarding inflammation, stress and neurodegeneration	How the biochemical profile in blood vary between individuals with MDD/SED and HC?	At baseline, i.e. at diagnosis, at first study-specific follow-up (12 months from baseline), and at second study-specific follow-up (24 months from baseline)
Secondary	Biochemical Profile in saliva regarding inflammation and stress	How the biochemical profile in saliva as described above vary between individuals with MDD/SED and HC?	At baseline, i.e. at diagnosis, at first study-specific follow-up (12 months from baseline), and at second study-specific follow-up (24 months from baseline)
Secondary	Biochemical Profile in hair regarding exposure to stress	How the biochemical profile in hair as described above vary between individuals with MDD/SED and HC?	At baseline, i.e. at diagnosis, at first study-specific follow-up (12 months from baseline), and at second study-specific follow-up (24 months from baseline)